Clinical research

A randomised comparison between everolimus-eluting stent and sirolimus-eluting stent in chronic coronary total occlusions. Rationale and design of the CIBELES (non-acute Coronary occlusion treated By EveroLimus-Eluting Stent) trial

EuroIntervention 2010;6:112-116.

Raul Moreno
Raúl Moreno1*, MD; Eulogio Garcia2, MD; Rui C. Teles3, MD; Manuel S. Almeida3; Henrique Cyrne Carvalho4, MD; Manel Sabate5, MD; Roberto Martin-Reyes1, MD; José Ramón Rumoroso6, MD; Guillermo Galeote1, MD; Francisco Javier Goicolea7, MD; José Moreu8, MD; Vicente Mainar9, MD; Josefa Mauri11, MD; Rui Ferreira12, MD; Mariano Valdes13, MD; Armando Perez de Prado14, MD; Victoria Martin-Yuste14, MD; Santiago Jimenez-Valero1; Angel Sanchez-Recalde1. University Hospital La Paz, Madrid, Spain; 2. Hospital Clinico San Carlos, Madrid, Spain; 3. Hospital Sta. Cruz, Lisboa, Portugal; 4. Hospital Sto. Antonio, Porto, Portugal; 5. Hospital Clinic, Barcelona, Spain; 6. Hospital de Galdakao, Bilbao, Spain;

Chronic total coronary occlusions constitute a sub-group of lesions at very high risk of restenosis after successful percutaneous coronary intervention. The sirolimus-eluting coronary stent is the only drug-eluti

Sign in to read and download the full article

Forgot your password?

No account yet?
Sign up for free!

Create my pcr account

Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from

coronary stentchronic coronary occlusiondrug-eluting stent
Read next article
Endothelial function rather than endothelial restoration is altered in paclitaxel- as compared to bare metal-, sirolimus and tacrolimus-eluting stents

Latest news